
浏览全部资源
扫码关注微信
1.北京中医药大学 中药学院 中药现代研究中心,北京 100029
2.北京电子科技职业学院 生物工程学院,北京 100029
杨爱琳,博士,从事中药活性成分抗肿瘤作用研究,E-mail:yangailin0418@163.com
屠鹏飞,教授,从事中药活性成分与新药开发研究,E-mail:pengfeitu@163.com
胡仲冬,研究员,从事中药活性成分抗肿瘤作用研究,E-mail:huzhongdong@126.com; *
收稿日期:2021-09-15,
网络出版日期:2021-11-08,
纸质出版日期:2022-01-05
移动端阅览
杨爱琳,黄惠铭,刘亚鑫等.槐耳蛋白聚糖TPG-1抑制人肝癌SK-HEP-1细胞生长的机制[J].中国实验方剂学杂志,2022,28(01):72-78.
YANG Ai-lin,HUANG Hui-ming,LIU Ya-xin,et al.Mechanism of Proteoglycan TPG-1 from Trametes robiniophila Inhibiting Growth of Human Hepatoma SK-HEP-1 Cells[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(01):72-78.
杨爱琳,黄惠铭,刘亚鑫等.槐耳蛋白聚糖TPG-1抑制人肝癌SK-HEP-1细胞生长的机制[J].中国实验方剂学杂志,2022,28(01):72-78. DOI: 10.13422/j.cnki.syfjx.20220126.
YANG Ai-lin,HUANG Hui-ming,LIU Ya-xin,et al.Mechanism of Proteoglycan TPG-1 from Trametes robiniophila Inhibiting Growth of Human Hepatoma SK-HEP-1 Cells[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(01):72-78. DOI: 10.13422/j.cnki.syfjx.20220126.
目的
2
蛋白聚糖TPG-1具有良好的抗肝癌活性,本研究进一步探究蛋白聚糖TPG-1抗肝癌的分子作用机制。
方法
2
用槐耳蛋白聚糖TPG-1(0,0.05,0.1,0.25,0.5,1 g·L
-1
)处理人肝癌SK-HEP-1细胞,采用噻唑蓝(MTT)比色法检测槐耳蛋白聚糖TPG-1对SK-HEP-1细胞增殖的影响,采用流式细胞术检测TPG-1对SK-HEP-1细胞凋亡的影响。对经TPG-1处理过的人肝癌SK-HEP-1细胞进行基因芯片检测分析,探讨TPG-1抗肝癌的分子作用机制。
结果
2
与空白组比较,槐耳蛋白聚糖TPG-1能够显著抑制人肝癌SK-HEP-1细胞的增殖能力(
P<
0.01)。TPG-1(1 g·L
-1
)作用于SK-HEP-1细胞48 h,SK-HEP-1细胞凋亡率显著增加(
P<
0.01),且TPG-1给药能够显著促进细胞凋亡重要执行者含半胱氨酸的天冬氨酸蛋白水解酶(Caspase)-3和Caspase-7的剪切水平(
P<
0.01)。与空白组比较,TPG-1(0.1 g·L
-1
)能够抑制SK-HEP-1细胞的迁移能力(
P<
0.05)。基因芯片检测分析结果显示,TPG-1处理后,SK-HEP-1细胞中差异表达基因有971个,其中表达上调基因486个,表达下调基因485个。基因本体(GO)和通路(Pathway)分析结果显示表达差异基因的功能主要涉及白细胞介素-6(IL-6)生物合成、抗原加工与呈递、超氧化物歧化酶活性、丝裂原活化蛋白激酶激酶激酶(MAPKKK)级联反应的正调控、自然杀伤(NK)细胞趋化、趋化因子生物合成等。此外,表达差异基因所涉及的信号通路主要包括核苷酸寡聚化结构域(NOD)样受体信号通路,凋亡,Toll样受体信号通路,维甲酸诱导基因-Ⅰ(RIG-Ⅰ)样受体信号通路,T细胞受体信号通路及趋化因子信号通路等。蛋白免疫印迹法结果显示,TPG-1(1 g·L
-1
)能够显著激活SK-HEP-1细胞中丝裂原活化蛋白激酶(MAPK)信号通路(
P<
0.01)。
结论
2
槐耳蛋白聚糖TPG-1能够抑制人肝癌SK-HEP-1细胞增殖及迁移能力并促进其发生凋亡,MAPK信号通路的激活可能与TPG-1发挥抑制人肝癌SK-HEP-1细胞生长作用有关。
Objective
2
Proteoglycan TPG-1 isolated from
Trametes robiniophila
(Huaier) has proved to have anti-hepatoma activity, and this paper aims to explore the molecular mechanism.
Method
2
Human hepatoma SK-HEP-1 cells were treated with TPG-1 (0, 0.05, 0.1, 0.25, 0.5, 1 g·L
-1
). Then cell survival was detected by methyl thiazolyl tetrazolium (MTT) and apoptosis by flow cytometry. In addition, expression of genes in SK-HEP-1 cells treated with or without TPG-1 was examined by DNA microarray to preliminarily explore the anti-hepatoma molecular mechanism of TPG-1.
Result
2
TPG-1 inhibited the proliferation of SK-HEP-1 cells as compared with the blank group (
P
<
0.01). After treatment with 1 g·L
-1
TPG-1 for 48 h, the apoptosis rate of SK-HEP-1 cells increased (
P<
0.01), and TPG-1 promoted the cleavage of cysteinyl aspartate specific proteinase (Caspase)-3 and Caspase-7, the key mediators of apoptosis (
P<
0.01). Additionally, TPG-1 (1 g·L
-1
) suppressed the migration of SK-HEP-1 cells (
P<
0.05). A total of 971 differentially expressed genes (DEGs) were identified in SK-HEP-1 cells after treatment with TPG-1, with 486 up-regulated and 485 down-regulated. These DEGs were mainly involved in the Gene Ontology (GO) terms of interleukin-6 (IL-6) biosynthesis, antigen processing and presentation, superoxide dismutase activity, positive regulation of mitogen-activated protein kinase kinase kinase (MAPKKK) cascade, nature killer (NK) cell chemotaxis, and chemokine biosynthesis, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of nucleotide-binding oligomerization domain (NOD)-like receptor signaling pathway, apoptosis, Toll-like receptor signaling pathway, retinoic acid-inducible gene-Ⅰ (RIG-Ⅰ)-like receptor signaling pathway, T-cell receptor signaling pathway, and chemokine signaling pathway. Western blot results showed that TPG-1 (1 g·L
-1
) activated mitogen-activated protein kinase (MAPK) signaling pathway in SK-HEP-1 cells (
P<
0.01).
Conclusion
2
Proteoglycan TPG-1 inhibited the proliferation and migration, and induced apoptosis of human hepatoma SK-HEP-1 cells. Up-regulation of MAPK signaling pathway may be responsible for the growth inhibition of human hepatoma SK-HEP-1 cells by TPG-1.
YANG J D , ROBERTS L R . Hepatocellular carcinoma: a global view [J]. Nat Rev Gastro Hepat , 2010 , 7 ( 8 ): 448 - 458 .
LLOVET J M , RICCI S , MAZZAFERRO V , et al . Sorafenib in advanced hepatocellular carcinoma [J]. N Engl J Med , 2008 , 359 ( 4 ): 378 - 390 .
MARISI G , CUCCHETTI A , ULIVI P , et al . Ten years of sorafenib in hepatocellular carcinoma: are there any predictive and/or prognostic markers? [J]. World J Gastroenterol , 2018 , 24 ( 36 ): 4152 - 4163 .
XIANG Y , GUO Z , ZHU P , et al . Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science [J]. Cancer Med , 2019 , 8 ( 5 ): 1958 - 1975 .
NIE J , ZHAO C , DENG LI , et al . Efficacy of traditional Chinese medicine in treating cancer [J]. Biomed Rep , 2016 , 4 ( 1 ): 3 - 14 .
杨爱琳 , 胡仲冬 , 屠鹏飞 . 槐耳抗肿瘤作用研究进展 [J]. 中国中药杂志 , 2015 , 40 ( 24 ): 4805 - 4810 .
张书琳 . 槐耳及其复方制剂槐杞黄颗粒的研究进展 [J]. 医学综述 , 2015 , 21 ( 1 ): 114 - 116 .
CHEN Q , SHU C , LAURENCE A , et al . Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial [J]. Gut , 2018 , 67 ( 11 ): 2006 - 2016 .
ZHENG J , LI C , WU X , et al . Huaier polysaccharides suppresses hepatocarcinoma MHCC97-H cell metastasis via inactivation of EMT and AEG-1 pathway [J]. Int J Biol Macromol , 2014 , 64 : 106 - 110 .
SUN Y , SUN T , WANG F , et al . A polysaccharide from the fungi of Huaier exhibits anti-tumor potential and immunomodulatory effects [J]. Carbohydr Polym , 2013 , 92 ( 1 ): 577 - 582 .
YANG A , FAN H , ZHAO Y , et al . An immune-stimulating proteoglycan from the medicinal mushroom Huaier up-regulates NF- κ B and MAPK signaling via Toll-like receptor 4 [J]. J Biol Chem , 2019 , 294 ( 8 ): 2628 - 2641 .
DHILLON A S , HAGAN S , RATH O , et al . MAP kinase signalling pathways in cancer [J]. Oncogene , 2007 , 26 ( 22 ): 3279 - 3290 .
BRENTANI R R , CARRARO D M , VERJOVSKIALMEIDA S , et al . Gene expression arrays in cancer research: methods and applications [J]. Crit Rev Oncol Hemat , 2005 , 54 ( 2 ): 95 - 105 .
刘天龙 , 李玉文 , 张一恺 , 等 . 基因芯片技术在中药药理作用机制研究中的应用 [J]. 中国药房 , 2016 , 27 ( 28 ): 4021 - 4024
王珊珊 , 廖清船 , 许静 , 等 . 基因芯片技术在中药肿瘤药理研究中的应用 [J]. 中国药房 , 2011 , 22 ( 31 ): 2968 - 2970 .
LI W F , JIANG J G , CHEN J . Chinese medicine and its modernization demands [J]. Arch Med Res , 2008 , 39 ( 2 ): 246 - 251 .
路秀英 , 王占长 . IL-1、IL-6与肿瘤的关系 [J]. 国外医学 , 1995 ( 3 ): 159 - 161 .
李性天 . 超氧化物歧化酶的作用机理及其抗肿瘤和抗心肌梗塞作用 [J]. 生化药物杂志 , 1988 ( 2 ): 16 - 19 .
杨春媚 , 张婷婷 , 钱程 , 等 . NK细胞抗肿瘤机制及相关免疫疗法的研究进展 [J]. 中国药理学通报 , 2019 , 35 ( 11 ): 1492 - 1496 .
辛崇美 , 徐秀莲 , 孙建方 . 趋化因子在肿瘤进展中的作用 [J]. 国际免疫学杂志 , 2014 , 37 ( 3 ): 183 - 186 .
BRAICU C , BUSE M , BUSUIOC C , et al . A comprehensive review on MAPK: a promising therapeutic target in cancer [J]. Cancers (Basel) , 2019 , doi: 10.3390/cancers11101618 http://dx.doi.org/10.3390/cancers11101618 .
WADA T , PENNINGER J M . Mitogen-activated protein kinases in apoptosis regulation [J]. Oncogene , 2004 , 23 ( 16 ): 2838 - 2849 .
0
浏览量
21
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621